View Older Stories View More Recent Stories

Jun 6, 2022 05:49AM Abbott (ABT) Reports Data Demonstrating Abbott's FreeStyle Libre 3 System is Most Accurate 14-Day Continuous Glucose Monitor
Jun 5, 2022 09:00AM Late-Breaking Data Demonstrate Abbott's FreeStyle Libre® 3 System is Most Accurate 14-Day Continuous Glucose Monitor
Jun 3, 2022 09:01AM Abbott (ABT) Developing Novel Continuous Glucose-Ketone Monitoring System
Jun 3, 2022 09:00AM Abbott Announces Development of Novel Continuous Glucose-Ketone Monitoring System
May 31, 2022 08:13AM Abbott's (ABT) FreeStyle Libre 3 Receives U.S. FDA Clearance
May 31, 2022 08:00AM Abbott's FreeStyle Libre® 3 Receives U.S. FDA Clearance - Features World's Smallest, Thinnest and Most Accurate 14-Day Glucose Sensor
May 24, 2022 05:11PM Abbott to Release EleCare® Amino Acid-based Formulas to Help Meet Critical Patient Need
May 19, 2022 09:15AM New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies
May 16, 2022 04:24PM Abbott (ABT) Enters into Consent Decree with FDA for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility
May 16, 2022 04:22PM Abbott Enters into Consent Decree with U.S. Food and Drug Administration for its Sturgis, Mich., Plant; Agreement Creates Pathway to Reopen Facility
May 11, 2022 09:00AM Abbott and Women as One Partner to Help More Underrepresented Physicians Lead Clinical Trials
May 4, 2022 09:01AM Abbott (ABT) Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
May 4, 2022 09:00AM Abbott Obtains FDA Clearance for First Test that Simultaneously Detects Four Common Sexually Transmitted Infections (STIs) as Cases are on the Rise
Apr 29, 2022 04:35PM Abbott to Release Metabolic Nutrition Formulas
Apr 29, 2022 09:02AM Abbott (ABT) Reports Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months
Apr 29, 2022 09:00AM Study Finds 89% of Patients Treated for Persistent Atrial Fibrillation Using Abbott's Ablation Device Remain Symptom-Free for at Least 15 Months
Apr 28, 2022 09:00AM Abbott Strengthens Left Atrial Appendage Closure Leadership With U.S. Availability of Amplatzer™ Steerable Delivery Sheath for the Company's Amulet™ Device
Apr 28, 2022 07:00AM New Analysis Shows that Abbott's FreeStyle Libre® System Provides Similar and Sustained Reductions in Glucose Levels for People with Both Type 1 and Type 2 Diabetes
Apr 27, 2022 08:00AM Abbott, CamDiab and Ypsomed Unveil New Automated Insulin Delivery Partnership for People with Diabetes
Apr 26, 2022 09:00AM Abbott Recommends Rejection of Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
Apr 25, 2022 09:00AM Abbott Strengthens Its Connected Care Technologies with Latest NeuroSphere™ myPath™ Digital Health App
Apr 20, 2022 07:30AM Abbott Reports First-Quarter 2022 Results
Apr 4, 2022 09:01AM Abbott (ABT) Receives FDA Approval for Aveir VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms
Apr 4, 2022 09:00AM Abbott Receives FDA Approval for Aveir™ VR Leadless Pacemaker System to Treat Patients with Slow Heart Rhythms
Mar 30, 2022 07:30AM Abbott and LISC Team Up to Address Diversity and Equity Gaps in the Healthcare Industry Supply Chain
Mar 28, 2022 09:00AM Abbott Hosts Conference Call for First-Quarter Earnings
Mar 24, 2022 09:00AM Abbott's FreeStyle® Libre is First and Only CGM System to Gain Expanded Reimbursement in Japan to Include All People with Diabetes Who Use Insulin
Feb 22, 2022 05:38AM Abbott's (ABT) CardioMEMS HF System Granted FDA Approval to Support Patients Battling Earlier-Stage Heart Failure
Feb 21, 2022 09:00AM Abbott's CardioMEMS™ HF System Receives FDA Approval to Support Patients Battling Earlier-Stage Heart Failure
Feb 18, 2022 11:26AM Abbott Declares 393rd Consecutive Quarterly Dividend
Feb 17, 2022 05:12PM Abbott (ABT) Announces Voluntarily Recall of Powder Formulas Manufactured at One Plant
Feb 17, 2022 05:11PM Abbott Voluntarily Recalls Powder Formulas Manufactured at One Plant
Feb 7, 2022 09:02AM Abbott (ABT) Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
Feb 7, 2022 09:00AM Abbott Announces World's First Implant of Dual-Chamber Leadless Pacemaker in Pivotal Trial
Jan 26, 2022 07:30AM Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast
Jan 12, 2022 09:02AM Abbott (ABT) Receives FDA Clearance for New Cardiac Mapping System
Jan 12, 2022 09:00AM Abbott Receives U.S. FDA Clearance for New Cardiac Mapping System to Improve How Doctors Treat Abnormal Heart Rhythms
Jan 6, 2022 01:18PM Abbott (ABT) Introduces Biowearables at CES
Jan 6, 2022 01:15PM Abbott Announces Future of Biowearables at Consumer Electronics Show
Jan 4, 2022 05:00PM Abbott Hosts Conference Call for Fourth-Quarter Earnings
Jan 4, 2022 09:00AM Abbott's Proclaim™ XR Spinal Cord Stimulation System Now Offers Expanded MRI Compatibility in U.S.
Dec 21, 2021 09:00AM Abbott to Present at J.P. Morgan Healthcare Conference
Dec 10, 2021 02:01PM Abbott (ABT) Names Robert Ford as Chairman
Dec 10, 2021 02:00PM Abbott Names Robert B. Ford Chairman of the Board; Miles D. White to Retire as Executive Chairman
Dec 10, 2021 01:00PM Abbott Increases Quarterly Dividend for 50th Consecutive Year
Nov 16, 2021 01:00PM Abbott Launches Similac® 360 Total Care® with Exclusive Blend of Five HMO Prebiotics and Designed to Support the Immune System, Digestive Health and Brain Development
Nov 15, 2021 10:48AM Abbott Achieves Highest Score in Its Industry for the Ninth Consecutive Year on the Dow Jones Sustainability Index (DJSI)
Nov 12, 2021 09:01AM Abbott's (ABT) New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
Nov 12, 2021 09:00AM Abbott's New Leadless Pacemaker System Meets Primary Endpoints in Pivotal Trial
Nov 9, 2021 09:00AM Abbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology
View More Recent Stories View Older Stories